TYK2 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Purchase Option

$ 4400
$ 6600
$ 8900

Non-receptor tyrosine-protein kinase TYK2 is an enzyme that in humans is encoded by the TYK2 gene. TYK2 was the first member of the JAK family that was described (the other members are JAK1, JAK2, and JAK3). It has been implicated in IFN-α, IL-6, IL-10, and IL-12 signaling. TYK2 Inhibitors are a class of drugs that target the TYK2 protein. TYK2 is an enzyme that plays a crucial role in the signaling pathways of various immune cells, including those involved in autoimmune and inflammatory diseases. By inhibiting the activity of TYK2, these drugs aim to modulate the immune response and reduce inflammation. TYK2 inhibitors are mainly being developed as potential treatments for autoimmune conditions such as rheumatoid arthritis, psoriasis, diabetes complications, fever, kidney diseases, urologic diseases, and inflammatory bowel disease.

By targeting TYK2, they can interfere with the signaling pathways that contribute to the inflammatory process and help alleviate the symptoms associated with these diseases. According to WHO, arthritis affects millions of people in Europe and the USA, causing significant pain and disability. In Europe, around 60 million people are affected by arthritis, with osteoarthritis and rheumatoid arthritis being the most prevalent types. In the USA, arthritis affects over 54 million adults. Growth drivers such as the Potential for treating autoimmune diseases, increasing prevalence of such conditions, demand for novel therapies, research advancements, and market expansion. Moreover, many leading market players such as BMS launched Sotyktu (Deucravacitinib) tablets for the treatment of plaque psoriasis and many other molecules are under various stages of clinical development.

Key Market Developments:

  • In September 2022, BMS received FDA approval for the Sotyktu (Deucravacitinib) tablets for the treatment of adults with moderate-to-severe plaque psoriasis.
  • In June 2022, Eli Lilly received an FDA grant for its Olumiant (Baricitinib) for an expanded indication of severe alopecia areata.

Approved Drug Molecules and Brand Names for TYK2 Inhibitors:

 Sotyktu (Deucravacitinib) tablets

Olumiant (Baricitinib)

Rinvoq (Upadacitinib)

Drugs under the Pipeline for TYK2 Inhibitors:

Brepocitinib (PF-06700841)

Izencitinib (TD-1473)



Gusacitinib (ASN002)

Ropsacitinib (PF-06826647)




Brepocitinib Topical Cream (PF-06700841 Topical)














TLL018 Extended Release

Clinical Activity and Developments of TYK2 Inhibitors:

Till July 2023, more than 20 companies have approximately 28 molecules targetting many autoimmune diseases. For these molecules, more than 150 clinical trials are being conducted and the majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,

  • In July 2020, Galapagos completed phase 1, a first-in-human randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of GLPG3667 in adult, healthy, male subjects.

Molecule Name

Number of Studies

Brepocitinib (PF-06700841)


Izencitinib (TD-1473)






Gusacitinib (ASN002)




Target Indication Analysis of TYK2 Inhibitors

The molecules such as Sotyktu (Deucravacitinib) tablets were developed by BMS which is specifically indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Moreover, Eli Lilly’s Olumiant (Baricitinib) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies, for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen and adult patients with severe alopecia areata.

Frequently Asked Questions

Sotyktu (Deucravacitinib) tablets, Olumiant (Baricitinib), and Rinvoq (Upadacitinib) are the few FDA-approved TYK2 Inhibitors

Incyte, Eli Lilly, AbbVie, and BMS are a few leading market players in TYK2 Inhibitors.

Major Indications for TYK2 Inhibitors are rheumatoid arthritis, psoriasis, diabetes complications, fever, kidney diseases, urologic diseases, and inflammatory bowel diseases among others

There are more than 20 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  •  Incyte
  •  Eli Lilly
  •  AbbVie
  •  BMS
  •  Astellas
  •  Priovant Therap
  •  Theravance Biopharma
  •  Galapagos
  •  Gilead
  •  Highlightll Pharma
  •  TrialSpark
  •  Priovant Therap
  •  BMS
  •  Alumis
  •  Ventyx Biosci
  •  Priovant Therapeutics
  •  BeiGene
  •  Celon Pharma

Adjacent Markets